Involvement of the long noncoding RNA NEAT1 in carcinogenesis.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
01 2019
Historique:
received: 25 07 2018
revised: 25 10 2018
accepted: 07 11 2018
pubmed: 16 11 2018
medline: 20 11 2019
entrez: 16 11 2018
Statut: ppublish

Résumé

Altered expression levels of the long noncoding RNA (lncRNA) nuclear-enriched abundant transcript 1 (NEAT1) have been reported in different types of cancer. More than half of the NEAT1 studies in cancer have been published within the last 2 years. In this review, we discuss very recent developments and insights into NEAT1 contribution to carcinogenesis. Summarizing the literature, it becomes obvious that NEAT1 is a lncRNA highly de-/upregulated in a variety of cancer entities, in which it primarily acts as a competing endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA). The sponged miRNA lose their ability to degrade, silence, or hamper translation of their downstream-mostly oncogenic-target transcripts, ultimately promoting carcinogenesis. This role of NEAT1 function in tumorigenesis suggests it may be a prognostic biomarker as well as potential therapeutic target, pending the completion of further studies into the underlying mechanisms.

Identifiants

pubmed: 30430751
doi: 10.1002/1878-0261.12404
pmc: PMC6322192
doi:

Substances chimiques

Biomarkers, Tumor 0
MicroRNAs 0
NEAT1 long non-coding RNA, human 0
RNA, Long Noncoding 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-60

Informations de copyright

© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Références

Onco Targets Ther. 2017 Feb 17;10:993-1000
pubmed: 28255245
Sci Rep. 2017 Oct 12;7(1):13080
pubmed: 29026116
Biosci Rep. 2018 May 31;38(3):
pubmed: 29654165
Gene Regul Syst Bio. 2016 Apr 27;10(Suppl 1):11-7
pubmed: 27147820
Onco Targets Ther. 2017 Nov 10;10:5377-5390
pubmed: 29180871
J Cell Physiol. 2018 Sep;233(9):6733-6741
pubmed: 29219178
RNA. 2014 Dec;20(12):1844-9
pubmed: 25316907
Curr Biol. 2002 Jan 8;12(1):13-25
pubmed: 11790299
Mol Cell. 2009 Mar 27;33(6):717-26
pubmed: 19217333
Mol Oncol. 2011 Dec;5(6):483-91
pubmed: 22079056
Int J Cancer. 2017 Jun 15;140(12):2785-2791
pubmed: 28295289
Eur Rev Med Pharmacol Sci. 2017 Feb;21(3):504-510
pubmed: 28239820
Int J Biochem Cell Biol. 2018 Jan;94:125-132
pubmed: 29225160
Arch Biochem Biophys. 2017 Feb 1;615:1-9
pubmed: 28034643
Br J Cancer. 2017 Jun 27;117(1):78-88
pubmed: 28571042
Dis Markers. 2017;2017:5314649
pubmed: 29147064
Oncotarget. 2016 Sep 20;7(38):62208-62223
pubmed: 27556696
Mol Cancer. 2018 May 15;17(1):90
pubmed: 29764424
Cancer Res. 2018 Aug 1;78(15):4138-4149
pubmed: 29871935
FEBS Lett. 2010 Apr 16;584(8):1531-5
pubmed: 20211624
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
pubmed: 14500907
J Cell Physiol. 2018 Nov;233(11):8578-8587
pubmed: 29797561
Mol Cell Pharmacol. 2011;3(3):83-92
pubmed: 22468167
J Clin Med. 2016 Jan 26;5(2):
pubmed: 26821054
Oncogene. 2015 Aug 20;34(34):4546
pubmed: 26289678
Biomed Pharmacother. 2017 Oct;94:612-618
pubmed: 28783584
Front Biol (Beijing). 2016 Dec;11(6):413-426
pubmed: 29033980
Cancer Res. 2005 Sep 1;65(17):7976-83
pubmed: 16140970
J Clin Invest. 2017 Sep 1;127(9):3421-3440
pubmed: 28805661
Cancer Lett. 2016 Jul 1;376(2):284-92
pubmed: 27063096
Mol Med Rep. 2018 Feb;17(2):2771-2777
pubmed: 29207151
Oncol Lett. 2017 Oct;14(4):4983-4988
pubmed: 29085511
Breast Cancer Res Treat. 2018 Jun;169(2):267-275
pubmed: 29388017
Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5756-E5765
pubmed: 29866826
Oncol Rep. 2018 Apr;39(4):1948-1956
pubmed: 29484420
Mol Cell Oncol. 2015 Oct 29;3(2):e1091061
pubmed: 27308613
Development. 2014 Dec;141(23):4618-27
pubmed: 25359727
Breast Cancer Res Treat. 2010 Aug;123(1):139-47
pubmed: 19921427
Pathol Res Pract. 2018 Dec;214(12):1993-1999
pubmed: 30279010
Int J Mol Sci. 2017 Nov 22;18(11):
pubmed: 29165391
Tumour Biol. 2015 Aug;36(8):5987-97
pubmed: 25731732
Oncotarget. 2017 Jan 10;8(2):2672-2680
pubmed: 27926523
Yonsei Med J. 2017 Nov;58(6):1092-1100
pubmed: 29047232
Cell. 2011 Oct 14;147(2):358-69
pubmed: 22000014
Biochem Biophys Res Commun. 2018 Sep 26;504(1):218-224
pubmed: 30180948
Cell. 2001 Aug 24;106(4):465-75
pubmed: 11525732
Oncotarget. 2017 Dec 18;9(2):2395-2409
pubmed: 29416780
Eur Rev Med Pharmacol Sci. 2017 Mar;21(5):1020-1026
pubmed: 28338194
Noncoding RNA. 2018 Mar 08;4(1):
pubmed: 29657304
Genes Dev. 2017 Jun 1;31(11):1095-1108
pubmed: 28698299
J Med Genet. 2015 Oct;52(10):710-8
pubmed: 26358722
Cancer Biol Ther. 2018 Jun 3;19(6):534-542
pubmed: 29565706
J Biol Chem. 2010 Apr 30;285(18):14042-51
pubmed: 20189993
Carcinogenesis. 2012 Apr;33(4):810-7
pubmed: 22301282
Oncogene. 2015 Sep 24;34(39):5003-11
pubmed: 25619839
Am J Physiol Gastrointest Liver Physiol. 2017 Aug 1;313(2):G150-G156
pubmed: 28526689
Oncotarget. 2016 Oct 4;7(40):65067-65089
pubmed: 27556296
Nat Rev Cancer. 2006 Jul;6(7):506-20
pubmed: 16794634
World J Gastroenterol. 2005 Feb 7;11(5):623-8
pubmed: 15655810
Onco Targets Ther. 2016 Jun 24;9:3815-27
pubmed: 27445486
PLoS One. 2013 Oct 16;8(10):e77702
pubmed: 24147060
Nat Genet. 2007 Aug;39(8):1033-7
pubmed: 17643101
PLoS One. 2012;7(4):e35800
pubmed: 22536440
Mol Cell. 2014 Feb 6;53(3):393-406
pubmed: 24507715
Biochem Biophys Res Commun. 2016 May 13;473(4):987-992
pubmed: 27049311
Eur Rev Med Pharmacol Sci. 2016 Aug;20(16):3373-7
pubmed: 27608895
J Cell Physiol. 2018 Nov;233(11):8558-8566
pubmed: 29323713
Oncotarget. 2017 May 10;8(38):62927-62938
pubmed: 28968960
Oncol Rep. 2017 Jan;37(1):555-562
pubmed: 27878295
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nat Rev Genet. 2016 May;17(5):272-83
pubmed: 27040487
Methods. 2016 Apr 1;98:158-165
pubmed: 26564236
BMC Genomics. 2007 Feb 01;8:39
pubmed: 17270048
Mol Oncol. 2014 Dec;8(8):1393-403
pubmed: 24954858
Clin Cancer Res. 2010 Nov 15;16(22):5511-21
pubmed: 20851854
Cell Cycle. 2015;14(4):481-7
pubmed: 25607528
Sci Rep. 2017 Jan 05;7:40127
pubmed: 28054653
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
EMBO J. 2008 Jun 18;27(12):1694-705
pubmed: 18497743
Cancer Sci. 2018 Jul;109(7):2188-2198
pubmed: 29790629
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Nat Med. 2016 Aug;22(8):861-8
pubmed: 27376578
Cell Cycle. 2018;17(16):1949-1966
pubmed: 30300116
Cytokine. 2017 Oct;98:42-50
pubmed: 28579221
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Science. 1985 Sep 27;229(4720):1390-3
pubmed: 3929382
Cancer Metastasis Rev. 2018 Mar;37(1):83-105
pubmed: 29247341
Oncol Res. 2018 Mar 5;26(2):289-296
pubmed: 28762332
Cancer Res. 2007 Oct 15;67(20):9762-70
pubmed: 17942906
RNA. 2017 Jun;23(6):872-881
pubmed: 28325845
Onco Targets Ther. 2017 Dec 11;10:5843-5853
pubmed: 29270022
Cancer Lett. 2018 Apr 28;420:91-96
pubmed: 29409809
Anticancer Res. 2001 Nov-Dec;21(6A):3799-806
pubmed: 11911250
Mol Cancer. 2017 Jun 14;16(1):104
pubmed: 28615056
Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2819-24
pubmed: 27424981
J Exp Clin Cancer Res. 2018 Oct 16;37(1):253
pubmed: 30326930
Oncotarget. 2017 Jul 26;8(41):70156-70171
pubmed: 29050268
Cancer Biomark. 2017 Sep 7;20(3):247-254
pubmed: 28946559
Cell Rep. 2018 Apr 3;23(1):297-312.e12
pubmed: 29617668
Nat Commun. 2017 Oct 4;8(1):783
pubmed: 28978906
Int J Oncol. 2018 Feb;52(2):453-460
pubmed: 29345294
Cell Commun Signal. 2018 Feb 20;16(1):8
pubmed: 29463261
Int J Biol Macromol. 2017 Dec;105(Pt 1):346-353
pubmed: 28720546
J Cell Biol. 2016 Sep 26;214(7):817-30
pubmed: 27646274
Mol Cell. 2009 Aug 28;35(4):467-78
pubmed: 19716791
J Cell Biochem. 2019 Apr;120(4):4827-4836
pubmed: 29363783
BMC Cancer. 2014 Sep 23;14:693
pubmed: 25245097
Int J Mol Sci. 2017 Feb 22;18(2):
pubmed: 28241429
Onco Targets Ther. 2017 Oct 06;10:4905-4915
pubmed: 29062236
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Genome Res. 1997 Jul;7(7):725-35
pubmed: 9253601
J Cell Physiol. 2018 Jun;233(6):4852-4863
pubmed: 29152741
Biochem Biophys Res Commun. 2018 Nov 2;505(3):931-938
pubmed: 30309647
Science. 1994 Oct 7;266(5182):66-71
pubmed: 7545954
Mol Cell. 2018 Jun 21;70(6):1038-1053.e7
pubmed: 29932899
Cell. 2005 Oct 21;123(2):249-63
pubmed: 16239143
Oncol Lett. 2017 Nov;14(5):5773-5778
pubmed: 29113206
Genes Cells. 2013 May;18(5):353-68
pubmed: 23489294
Mol Biol Cell. 2005 Nov;16(11):5304-15
pubmed: 16148043
Exp Biol Med (Maywood). 2018 Mar;243(5):473-480
pubmed: 29368542
J Cell Biochem. 2019 Mar;120(3):2836-2846
pubmed: 29095526
J Cell Biol. 2011 Apr 4;193(1):31-9
pubmed: 21444682
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2525-30
pubmed: 19188602
Mol Biol Cell. 2014 Jan;25(1):169-83
pubmed: 24173718
Nat Commun. 2014 Nov 21;5:5383
pubmed: 25415230
Cancer Lett. 2018 May 1;421:94-102
pubmed: 29458141
Cell Cycle. 2007 Apr 15;6(8):919-26
pubmed: 17404509
Nat Methods. 2007 Sep;4(9):721-6
pubmed: 17694064
Genetics. 2013 Mar;193(3):651-69
pubmed: 23463798
Dev Growth Differ. 2012 Jan;54(1):44-54
pubmed: 22070123
Genes Dev. 2015 Mar 15;29(6):630-45
pubmed: 25792598
Cell Prolif. 2017 Apr;50(2):
pubmed: 28105699
Cancer Treat Rev. 2016 Dec;51:1-9
pubmed: 27788386

Auteurs

Christiane Klec (C)

Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Austria.
Research Unit for Non-coding RNAs and Genome Editing, Medical University of Graz (MUG), Austria.

Felix Prinz (F)

Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Austria.
Research Unit for Non-coding RNAs and Genome Editing, Medical University of Graz (MUG), Austria.

Martin Pichler (M)

Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Austria.
Research Unit for Non-coding RNAs and Genome Editing, Medical University of Graz (MUG), Austria.
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH